Abstract
In 15 patients suffering from Paget's disease, the serum levels of alkaline phosphatase (ALP), 25-hydroxycholecalciferol (25OHD3), 24,25-dihydroxycholecalciferol (24,25 [OH] 2D3), 1,25-dihydroxycholecalciferol (1,25 [OH] 2D3), and parathormone (PTH) as well as urinary excretion of hydroxyproline (HP) have been determined before and after three-month calcitonin therapy. Before therapy, high concentrations of serum ALP and urinary HP excretion had been observed, whereas serum levels of 24,25 (OH) 2D3 were below the lower limit of the normal range. Calcitonin therapy caused a 31% reduction in ALP and a 50% reduction in HP, as well as a significant increase in serum levels of 24,25 (OH) 2D3; the levels of 25OHD3, 1,25 (OH) 2D3, and PTH remained unchanged after treatment. The significant negative correlation between 24,25 (OH) 2D3 and ALP and HP before and after calcitonin therapy suggests that in Paget's disease there is an uncompensated increased bone usage of 24,25 (OH) 2D3.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
